Company profile: Invitae
1.1 - Company Overview
Company description
- Provider of medical genetics services delivering comprehensive genetic information to guide healthcare decisions. Offers genetic testing for diseases and medical conditions; genetic counseling at no additional cost in specified regions; a Billing Assurance Program for cost-effective payment options; Invitae Generation using advanced machine learning for testing and classification; proactive health tests focusing on cancer and cardiovascular conditions; and sponsored no-charge testing via biopharma partnerships.
Products and services
- Genetic Counseling Services: Evidence-based consultations interpreting genetic test results and supporting health decisions, available at no additional cost in specified regions
- Genetic Testing: Medical-grade assays delivering comprehensive genetic information to guide health decisions for diseases and medical conditions, engineered to bring genetics into mainstream medicine for improved healthcare
- Invitae Generation: Machine learning–driven service utilizing advanced algorithms for genetic testing and classification, architected to support testing and classification across diseases and medical conditions
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Invitae
Cygnus Technologies
HQ: United States
Website
- Description: Provider of generic kits, immunoassay reagents, and antibody and assay development services to pharmaceutical and biotechnology industries. Specializes in custom antibody and assay development for host cell protein detection in recombinant pharmaceuticals and supplies specialized analytical products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cygnus Technologies company profile →
eGenesis
HQ: United States
Website
- Description: Provider of gene editing and genome engineering solutions to create human-compatible porcine organs and cells for transplantation. Offers HuCo organs and cells via the EGEN Platform, which addresses cross-species molecular incompatibilities and viral risks, enabling xenotransplantation to help address the global organ shortage.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full eGenesis company profile →
MultiVir
HQ: United States
Website
- Description: Provider of clinical-stage gene therapies, including investigational Ad-p53 and Ad-IL24 tumor suppressor immune gene therapies delivering normal genes into tumors to restore suppressor functions and stimulate anti-tumor responses; an Ad-p53 dendritic cell therapeutic vaccine; and combination regimens with anti-PD-1/PD-L1 for recurrent/metastatic cancers and advanced melanoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MultiVir company profile →
Catalog
HQ: United States
Website
- Description: Provider of a data conversion and storage platform used to offer next-generation digital data archives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Catalog company profile →
Scribe Therapeutics
HQ: United States
Website
- Description: Provider of CRISPR-based therapeutic platforms and medicines, including X-Editing (XE) technologies for high-activity, specific, deliverable gene editing; CRISPR by Design optimization; ELXR CasX-based epigenetic repressors; in vivo CRISPR genetic medicines (e.g., for sickle cell) with non-viral delivery; and ex vivo natural killer (NK) cell therapies for cancer in collaboration with Sanofi.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scribe Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Invitae
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Invitae
2.2 - Growth funds investing in similar companies to Invitae
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Invitae
4.2 - Public trading comparable groups for Invitae
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →